Literature DB >> 21343454

Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus.

Beibei Liang1, Nan Bai, Yun Cai, Rui Wang, Karl Drlica, Xilin Zhao.   

Abstract

MIC- and mutant prevention concentration (MPC)-based pharmacokinetic/pharmacodynamic (PK/PD) indices were compared for suitability as attainment targets for restricting amplification of levofloxacin-resistant mutant subpopulations. When three Staphylococcus aureus strains were examined with a hollow-fiber PK/PD model, area under the concentration-time curve over 24 h (AUC24)/MPC values of >25 and maximum concentration of drug in serum (Cmax)/MPC values of >2.2 predicted resistance outcome among different isolates with an interisolate kappa coefficient of 1. MIC-based mutant-restrictive PK/PD values varied >8-fold and exhibited only a moderate interisolate agreement (kappa coefficient of 0.5). Thus, MPC-based PK/PD indices are more suitable than MIC-based indices for predicting mutant-restricting fluoroquinolone doses when multiple bacterial isolates are considered.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21343454      PMCID: PMC3088181          DOI: 10.1128/AAC.00975-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Authors:  Nelson Jumbe; Arnold Louie; Robert Leary; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; Christopher Freeman; James B Kahn; Karen Bush; Michael N Dudley; Michael H Miller; George L Drusano
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 2.  A unified anti-mutant dosing strategy.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Antimicrob Chemother       Date:  2008-06-10       Impact factor: 5.790

Review 3.  The antibiotic selective process: concentration-specific amplification of low-level resistant populations.

Authors:  F Baquero; M C Negri; M I Morosini; J Blázquez
Journal:  Ciba Found Symp       Date:  1997

Review 4.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

5.  Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.

Authors:  Xilin Zhao; William Eisner; Nathan Perl-Rosenthal; Barry Kreiswirth; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

6.  Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.

Authors:  Hans-Jörg Linde; Norbert Lehn
Journal:  J Antimicrob Chemother       Date:  2003-12-19       Impact factor: 5.790

Review 7.  Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.

Authors:  Jerome J Schentag; Alison K Meagher; Alan Forrest
Journal:  Ann Pharmacother       Date:  2003-10       Impact factor: 3.154

8.  Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica.

Authors:  L P Randall; S W Cooles; L J V Piddock; M J Woodward
Journal:  J Antimicrob Chemother       Date:  2004-07-08       Impact factor: 5.790

Review 9.  Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.

Authors:  Jerome J Schentag; Alison K Meagher; Alan Forrest
Journal:  Ann Pharmacother       Date:  2003-09       Impact factor: 3.154

Review 10.  Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.

Authors:  Charles W Stratton
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more
  18 in total

1.  Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators.

Authors:  Natalia R Morero; Mariela R Monti; Carlos E Argaraña
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

2.  Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.

Authors:  Xin Li; Lin Wang; Xian-Jia Zhang; Yang Yang; Wei-Tao Gong; Bin Xu; Ying-Qun Zhu; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

3.  Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.

Authors:  Chengchun Sun; Junwen Hao; Meiqin Dou; Yanwen Gong
Journal:  J Antibiot (Tokyo)       Date:  2014-11-05       Impact factor: 2.649

4.  Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.

Authors:  Ai-Jun Pan; Qing Mei; Ying Ye; Hong-Ru Li; Bao Liu; Jia-Bin Li
Journal:  J Antibiot (Tokyo)       Date:  2016-10-19       Impact factor: 2.649

5.  The Inactivation of intrinsic antibiotic resistance determinants widens the mutant selection window for quinolones in Stenotrophomonas maltophilia.

Authors:  Guillermo García-León; María B Sánchez; José L Martínez
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

6.  Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations.

Authors:  Alexander A Firsov; Elena N Strukova; Darya S Shlykova; Yury A Portnoy; Varvara K Kozyreva; Mikhail V Edelstein; Svetlana A Dovzhenko; Mikhail B Kobrin; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

7.  Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.

Authors:  Elena N Strukova; Yury A Portnoy; Andrey V Romanov; Mikhail V Edelstein; Stephen H Zinner; Alexander A Firsov
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

8.  Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection model.

Authors:  W Ni; X Song; J Cui
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-14       Impact factor: 3.267

9.  In vitro potency and efficacy favor later generation fluoroquinolones for treatment of canine and feline Escherichia coli uropathogens in the United States.

Authors:  Xiaoqiang Liu; Dawn M Boothe; Yaping Jin; Kamoltip Thungrat
Journal:  World J Microbiol Biotechnol       Date:  2012-11-08       Impact factor: 3.312

10.  In vivo antimicrobial activity of marbofloxacin against Pasteurella multocida in a tissue cage model in calves.

Authors:  Changfu Cao; Ying Qu; Meizhen Sun; Zhenzhen Qiu; Xianhui Huang; Binbin Huai; Yan Lu; Zhenling Zeng
Journal:  Front Microbiol       Date:  2015-07-24       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.